Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 38, 2014 - Issue 5
200
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with β-Thalassemia Major

, , , , , & show all
Pages 365-368 | Received 16 Nov 2013, Accepted 08 Feb 2014, Published online: 30 Jul 2014

References

  • Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373–383
  • Mokhtar GM, Gadallah M, El Sherif NH, Ali HT. Morbidities and mortality in transfusion-dependent β-thalassemia patients (single-center experience). Pediatr Hematol Oncol. 2013;30(2):93–103
  • Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur J Haematol. 2012;89(3):187–197
  • Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–2483
  • Levey AS, Coresh J, Greene T, et al. Chronic kidney disease epidemiology C: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254
  • Inker LA, Okparavero A. Cystatin C as a marker of glomerular filtration rate: prospects and limitations. Curr Opin Nephrol Hypertens. 2011;20(6):631–639
  • Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2001;40(2):221–226
  • Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832–1843
  • Rule AD, Bergstralh EJ, Slezak JM, et al. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int. 2006;69(2):399–405
  • Blirup-Jensen S. Protein standardization II: Dry mass determination procedure for the determination of the dry mass of a pure protein precipitation. Clin Chem Lab Med 2001;39(11):1090–1097
  • Al-Khabori M, Bhandari S, Al-Huneini M, et al. Side effects of deferasirox iron chelation in patients with β thalassemia major or intermedia. Oman Med J. 2013;28(2):121–124
  • Dubourg L, Laurain C, Ranchin B, et al. Deferasirox-induced renal impairment in children: An increasing concern for pediatricians. Pediatr Nephrol. 2012;27(11):2115–2122
  • Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154(3):387–397
  • Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508
  • Moriya T, Tsuchiya A, Okizaki S, et al. Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes. Kidney Int. 2012;81(5):486–493
  • Woredekal Y. Early detection and treatment of diabetic nephropathy. Pediatr Endocrinol Rev. 2008;5(Suppl 4):999–1004
  • Filler G, Huang SH, Yasin A. The usefulness of cystatin C and related formulae in pediatrics. Clin Chem Lab Med 2012;50(12):2081–2091
  • ten Bosch JJ, Angmar-Mansson B. Characterization and validation of diagnostic methods. Monogr Oral Sci. 2000;17:174–189

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.